ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,086.37
0.61%
Dow Jones
44,156.73
0.30%
US Dollar vs MXN
20.494
-0.04%
Brent Oil
78.08
-0.33%
Bitcoin
102,228.25
-1.36%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Arbutus Biopharma Corporation (ABUS) Cotización

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

NASDAQ
3.22
0.01
(0.31%)
Cerrado 22 Enero 3:00PM
Delayed by 15 minutes
3.18
-0.04
(-1.24%)
Fuera de horario: 6:14PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
3.18
Postura de Compra
3.15
Postura de Venta
3.22
Volume Operado de la Acción
371,273
3.175 Rango del Día 3.255
2.265 Rango de 52 semanas 4.725
Capitalización de Mercado [m]
602.584M
Precio Anterior
3.21
Precio de Apertura
3.23
Hora
10
@
3.2183
Última hora de negociación
Volumen financiero
US$ 1,194,817
Precio Promedio Ponderado
3.2182
Volumen promedio (3 m)
852,345
Acciones en circulación
189,491,685
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-8.38
Beneficio por acción (BPA)
-0.38
turnover
18.14M
Beneficio neto
-72.85M

Acerca de Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.tekmirapharm.com
Sede
Burnaby, British Columbia, Can
Fundado
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.21. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 2.265 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares in issue. The market capitalisation of Arbutus Biopharma is US$608.27 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.38.

ABUS Últimas noticias

Más noticias

Form 8-K - Current report

13 Enero 2025
Edgar (US Regulatory)

Arbutus Provides 2025 Corporate and Financial Update

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025...

13 Enero 2025
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

05 Diciembre 2024
Edgar (US Regulatory)

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...

03 Diciembre 2024
Business Wire

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

26 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

15 Noviembre 2024
Edgar (US Regulatory)

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

15 Noviembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Noviembre 2024
Edgar (US Regulatory)

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

14 Noviembre 2024
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

06 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.09-2.752293577983.273.373.166304303.23032158CS
40.030.9523809523813.153.543.1158068623.28040829CS
12-0.85-21.09181141444.034.033.118523453.48139367CS
26-0.52-14.05405405413.74.7253.119729523.81138603CS
520.7933.05439330542.394.7252.26510780683.34429039CS
1560.6224.218752.564.7251.6910204322.84549677CS
2600.082.580645161293.190.8821411753.71864601CS

ABUS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Arbutus Biopharma?
El precio actual de las acciones de Arbutus Biopharma es US$ 3.18
¿Cuántas acciones de Arbutus Biopharma están en circulación?
Arbutus Biopharma tiene 189,491,685 acciones en circulación
¿Cuál es la capitalización de mercado de Arbutus Biopharma?
La capitalización de mercado de Arbutus Biopharma es USD 608.27M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Arbutus Biopharma?
Arbutus Biopharma ha negociado en un rango de US$ 2.265 a US$ 4.725 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Arbutus Biopharma?
El ratio precio/beneficio de Arbutus Biopharma es -8.38
¿Cuál es el ratio de efectivo a ventas de Arbutus Biopharma?
El ratio de efectivo a ventas de Arbutus Biopharma es 33.65
¿Cuál es la moneda de reporte de Arbutus Biopharma?
Arbutus Biopharma presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Arbutus Biopharma?
El último ingresos anual de Arbutus Biopharma es USD 18.14M
¿Cuál es el último beneficio anual de Arbutus Biopharma?
El último beneficio anual de Arbutus Biopharma es USD -72.85M
¿Cuál es la dirección registrada de Arbutus Biopharma?
La dirección registrada de Arbutus Biopharma es 100, 8900 GLENLYON PARKWAY, GLENLYON BUSINESS PARK, BURNABY, BRITISH COLUMBIA, V5J 5J8
¿Cuál es la dirección del sitio web de Arbutus Biopharma?
La dirección del sitio web de Arbutus Biopharma es www.tekmirapharm.com
¿En qué sector industrial opera Arbutus Biopharma?
Arbutus Biopharma opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
ASSTAsset Entities Inc
US$ 1.36
(51.11%)
121.68M
STAIScanTech AI Systems Inc
US$ 2.12
(44.22%)
51.68M
JYDJayud Global Logistics Ltd
US$ 3.53
(42.91%)
1.27M
NTRBNutriband Inc
US$ 7.39
(41.84%)
3.88M
STFSStar Fashion Culture Holdings Ltd
US$ 2.62
(-80.61%)
30.25M
HEPAHepion Pharmaceuticals Inc
US$ 0.135
(-58.05%)
39.89M
STBXStarBox Group Holdings Ltd
US$ 0.6201
(-36.50%)
1.63M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 93.51
(-35.73%)
1
JUNSJupiter Neurosciences Inc
US$ 3.61
(-33.39%)
6.87M
IPAImmunoPrecise Antibodies Ltd
US$ 0.6446
(30.75%)
296.43M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.3191
(33.57%)
229.11M
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
NVDANVIDIA Corporation
US$ 147.07
(4.43%)
216.62M
RGTIRigetti Computing Inc
US$ 13.89
(-0.64%)
154.54M

ABUS Discussion

Ver más
MWM MWM 1 semana hace
ABUS made it on mad money tonight, the ultimate spec! 

https://www.cnbc.com/2025/01/13/cramers-lightning-round-arbutus-biopharma-is-the-ultimate-spec.html
👍️ 1
MWM MWM 1 semana hace
I'll look now 👍🏽
👍️0
db7 db7 1 semana hace
MWM see today’s update. Qilu milestones coming and no more atm

Pfizer Markman results ‘soon’. Assuming they are positive we should have liftoff. ATM program killed the Moderna Markman last year and won’t be used during Pfizer results it sounds like

Now to just get a decisive victory!?!???
👍️0
db7 db7 2 meses hace
nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
👍️0
db7 db7 2 meses hace
2 days to AASLD...
👍️0
mick mick 3 meses hace
👍️0
db7 db7 3 meses hace
2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
👍️0
mick mick 4 meses hace
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 5 meses hace
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 5 meses hace
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 5 meses hace
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 5 meses hace
ABUS over $4
👍️0
Monksdream Monksdream 5 meses hace
ABUS under $4
👍️0
DewDiligence DewDiligence 6 meses hace
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 6 meses hace
Not for long! $ABUS$
👍️0
Monksdream Monksdream 6 meses hace
ABUS under $4
👍️0
mick mick 6 meses hace
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 6 meses hace
ABUS new 52/week high
👍️0
db7 db7 6 meses hace
👍️0
db7 db7 7 meses hace
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 8 meses hace
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 8 meses hace
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 8 meses hace
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 8 meses hace
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 8 meses hace
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 8 meses hace
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 8 meses hace
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 8 meses hace
Nice!
👍️0
db7 db7 8 meses hace
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 8 meses hace
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 9 meses hace
ABUS under $3
👍️0
mick mick 9 meses hace
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 10 meses hace
ABUS new 52 hi
👍️0
db7 db7 10 meses hace
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 10 meses hace
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 10 meses hace
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 10 meses hace
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 10 meses hace
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 10 meses hace
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 10 meses hace
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 10 meses hace
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0
MWM MWM 10 meses hace
Watching all 3 stocks. $ABUS is kind of moving...
👍️0
db7 db7 10 meses hace
was going to take all '3' to explode imo..
👍️0
MWM MWM 10 meses hace
Yes, I'm trying to read it myself
👍️0
db7 db7 10 meses hace
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
👍️0
db7 db7 10 meses hace
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 11 meses hace
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 11 meses hace
Handle on twitter is @DesertDweller93
👍️0
MWM MWM 11 meses hace
Great post!

What’s your handle on Twitter?
👍️0
Desert dweller Desert dweller 11 meses hace
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
👍️0

Su Consulta Reciente

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados